Lonza's Conrad Roten and David Lyon explain why integrated drug substance and drug product services can help shorten First-In-Human (FIH) trial and drug commercialisation timelines.
Following on from their recent partnership with Israel Biotech Fund (IBF), EPM caught up with Lonza's Pnina Weitz on the importance of early-stage support for emerging companies, and how robust strategies early on can pave a way to commercialisation.
In a keynote session at CPHI North America, Stephanie Gaulding, executive director of regulatory compliance at Pharmatech Associates, calls for innovators to look closely at the frameworks they agree to and work to mitigate future challenges.
Calvin Kim, senior director and head of IT Quality Systems & Validation at Samsung Biologics explores the fundamentals of data integrity and why a lack of critical strategic thinking could be affecting the success of implementing the technology.
Mark W. Womack, CEO of Stelis Biopharma, shares his views on the speed and compliance balancing act to achieve quality during a contract manufacturing operation.
In this case study, Carl Brookes - vice president of Manufacturing & Supply Chain operations at Kindeva Drug Delivery & product commercialisation manager Francis Mackin explore what CDMOs should be doing to prepare for Brexit.
EPM speaks to Patrick Malone, vice president, Operations, Contract Manufacturing at West Pharmaceutical Services, about the essentials in contract manufacturing and the latest trends affect manufacturers.
Anna Lukyanova, COO of life sciences compliance proivider Arriello, explains why tight project management is essential for success in pharma outsourcing.
